Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...
Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed ...
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...
Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...